Murall C. L. auteur aut IRD Reyne B. auteur aut IRD Selinger Christian auteur aut IRD Bernat C. auteur aut IRD Boue V. auteur aut IRD Grasset S. auteur aut IRD Groc S. auteur aut IRD Rahmoun M. auteur aut IRD Bender N. auteur aut IRD Bonneau M. auteur aut IRD Foulongne V. auteur aut IRD Graf C. auteur aut IRD Picot E. auteur aut IRD Picot M. C. auteur aut IRD Tribout V. auteur aut IRD Waterboer T. auteur aut IRD Bravo I. G. auteur aut IRD Reynes J. auteur aut IRD Segondy M. auteur aut IRD Boulle N. auteur aut IRD Alizon S. auteur aut IRD text journalArticle eng text/pdf born digital access Understanding genital infections by Human papillomaviruses (HPVs) remains a major public health issue, especially in countries where vaccine uptake is low. We investigate HPV prevalence and antibody status in 150 women (ages 18 to 25) in Montpellier, France. At inclusion and one month later, cervical swabs, blood samples and questionnaires (for demographics and behavioural variables) were collected. Oncogenic, non-vaccine genotypes HPV51, HPV66, HPV53, and HPV52 were the most frequently detected viral genotypes overall. Vaccination status, which was well-balanced in the cohort, showed the strongest (protective) effect against HPV infections, with an associated odds ratio for alphapapillomavirus detection of 0.45 (95% confidence interval: [0.22;0.58]). We also identified significant effects of age, number of partners, body mass index, and contraception status on HPV detection and on coinfections. Type-specific IgG serological status was also largely explained by the vaccination status. IgM seropositivity was best explained by HPV detection at inclusion only. Finally, we identify a strong significant effect of vaccination on genotype prevalence, with a striking under-representation of HPV51 in vaccinated women. Variations in HPV prevalence correlate with key demographic and behavioural variables. The cross-protective effect of the vaccine against HPV51 merits further investigation. specialized HPV Vaccination Serology Cross-protection Acute infections Genital infections 050 052 38 51 8167-8174 2020 0264-410X https://www.documentation.ird.fr/hor/fdi:010080509 10.1016/j.vaccine.2020.10.078 0264-410X [F B010080509] https://www.documentation.ird.fr/hor/fdi:010080509 https://www.documentation.ird.fr/intranet/publi/2021/01/010080509.pdf Accès réservé (Intranet de l'IRD) IRD - Base Horizon / Pleins textes 2021-02-08 2025-02-24 fdi:010080509 fre